课题基金 / 基金详情

CORE--VECTOR FACILITY

CORE--VECTOR FACILITY
核心——矢量设施
批准号:
6496720
负责人:
NICHOLAS MUZYCZKA
金额:
$18.75万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-08-01 至 2002-07-31

项目摘要

项目成果

NICHOLAS MUZYCZKA的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The Vector Core plays an integral and essential role in the production of research grade recombinant viral vectors for all of the investigators in the Program. It is critical that all investigators be provided with consistently high titer, pure rAAV preparations. It is particularly important that preps be free of replication-competent AAV (rcAAV) and have a particle to infectivity ratio of 200 or less. Therefore, the primary objective of the Vector Core is to make the highest quality vector possible for the investigators. Each virus preparation will be produced using a mini-Ad plasmid DNA system (to essentially eliminate wtAd contamination) and will be purified by a novel method utilizing iodixanol gradient centrifugation followed by heparin affinity chromatography. All virus stocks are subject to quality control assays to assess purity, particle titer, infectious titer, and potential contamination by rcAAV. The second objective of the Vector Core is to develop and implement improved methods in the process of scaling production and purification of rAAV. The Core is to develop and implement improved methods in the process of scaling production and purification of rAAV. The Vector Core is currently working on issues of scale-up production, including development of better helper systems. Additionally, we are testing new purification methods that include a variety of FPLC chromatography formats. Not only is the Vector Core able to make high quality rAAV virus preparations, but the Vector Core is also available to provide consulting on and/or actually perform vector construction and to aid in the development of biological assays is necessary for transgene screening. The Vector Core has already made available a variety of promoter-marker gene constructs for general screening.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Identifying and testing new targets for Parkinson Disease gene therapy
  • 批准号:
    8151115
  • 项目类别:
  • 资助金额:
    $31.41万
  • 财政年份:
    2010
  • 负责人:
    NICHOLAS MUZYCZKA
  • 依托单位:
Identifying and testing new targets for Parkinson Disease gene therapy
  • 批准号:
    8521403
  • 项目类别:
  • 资助金额:
    $30.31万
  • 财政年份:
    2010
  • 负责人:
    NICHOLAS MUZYCZKA
  • 依托单位:
Identifying and testing new targets for Parkinson Disease gene therapy
  • 批准号:
    8311777
  • 项目类别:
  • 资助金额:
    $31.41万
  • 财政年份:
    2010
  • 负责人:
    NICHOLAS MUZYCZKA
  • 依托单位:
Identifying and testing new targets for Parkinson Disease gene therapy
  • 批准号:
    8704739
  • 项目类别:
  • 资助金额:
    $31.09万
  • 财政年份:
    2010
  • 负责人:
    NICHOLAS MUZYCZKA
  • 依托单位:
海外基金